B7 score and T cell infiltration stratify immune status in prostate cancer
BackgroundAlthough immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers, exhibit prominent antitumor effects against numerous malignancies, their benefit for patients with prostate cancer (PCa) has been somewhat margin...
Saved in:
| Published in | Journal for immunotherapy of cancer Vol. 9; no. 8; p. e002455 |
|---|---|
| Main Authors | , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BMJ Publishing Group LTD
01.08.2021
BMJ Publishing Group |
| Series | Original research |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | BackgroundAlthough immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers, exhibit prominent antitumor effects against numerous malignancies, their benefit for patients with prostate cancer (PCa) has been somewhat marginal. This study aimed to assess the feasibility of B7-H3 or HHLA2 as alternative immunotherapeutic targets in PCa.MethodsImmunohistochemistry was performed to evaluate the expression pattern of PD-L1, B7-H3 and HHLA2 and the infiltration of CD8+ and Foxp3+ lymphocytes in 239 PCa tissues from two independent cohorts. The correlations between B7-H3 and HHLA2 and clinicopathological features, including the presence of CD8+ and Foxp3+ tumor-infiltrating lymphocytes (TILs), were explored.ResultsHHLA2 expression was much higher than PD-L1 expression but lower than B7-H3 expression in PCa tissues. High expression of both B7-H3 and HHLA2 was significantly associated with higher Gleason score and tumor stage, lymph node metastasis and dismal overall survival (OS) and cancer-specific survival (CSS). Moreover, a high B7 score, defined as high B7-H3 expression and/or high HHLA2 expression, was an independent prognostic predictor for PCa. Of note, a high B7 score was negatively correlated with CD8+ TILs. Importantly, a new immune classification, based on the B7 score and CD8+ TILs, successfully stratified OS and CSS in PCa.ConclusionsBoth B7-H3 and HHLA2 have a critical impact on the immunosuppressive microenvironment, and the B7 score could be used as an independent prognostic factor for PCa. The B7 score combined with CD8+ TILs could be used as a new immune classification to stratify the risk of death, especially cancer-related death, for patients with PCa. These findings may provide insights that could improve response to immune-related comprehensive therapy for PCa in the future. |
|---|---|
| AbstractList | Although immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers, exhibit prominent antitumor effects against numerous malignancies, their benefit for patients with prostate cancer (PCa) has been somewhat marginal. This study aimed to assess the feasibility of B7-H3 or HHLA2 as alternative immunotherapeutic targets in PCa.BACKGROUNDAlthough immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers, exhibit prominent antitumor effects against numerous malignancies, their benefit for patients with prostate cancer (PCa) has been somewhat marginal. This study aimed to assess the feasibility of B7-H3 or HHLA2 as alternative immunotherapeutic targets in PCa.Immunohistochemistry was performed to evaluate the expression pattern of PD-L1, B7-H3 and HHLA2 and the infiltration of CD8+ and Foxp3+ lymphocytes in 239 PCa tissues from two independent cohorts. The correlations between B7-H3 and HHLA2 and clinicopathological features, including the presence of CD8+ and Foxp3+ tumor-infiltrating lymphocytes (TILs), were explored.METHODSImmunohistochemistry was performed to evaluate the expression pattern of PD-L1, B7-H3 and HHLA2 and the infiltration of CD8+ and Foxp3+ lymphocytes in 239 PCa tissues from two independent cohorts. The correlations between B7-H3 and HHLA2 and clinicopathological features, including the presence of CD8+ and Foxp3+ tumor-infiltrating lymphocytes (TILs), were explored.HHLA2 expression was much higher than PD-L1 expression but lower than B7-H3 expression in PCa tissues. High expression of both B7-H3 and HHLA2 was significantly associated with higher Gleason score and tumor stage, lymph node metastasis and dismal overall survival (OS) and cancer-specific survival (CSS). Moreover, a high B7 score, defined as high B7-H3 expression and/or high HHLA2 expression, was an independent prognostic predictor for PCa. Of note, a high B7 score was negatively correlated with CD8+ TILs. Importantly, a new immune classification, based on the B7 score and CD8+ TILs, successfully stratified OS and CSS in PCa.RESULTSHHLA2 expression was much higher than PD-L1 expression but lower than B7-H3 expression in PCa tissues. High expression of both B7-H3 and HHLA2 was significantly associated with higher Gleason score and tumor stage, lymph node metastasis and dismal overall survival (OS) and cancer-specific survival (CSS). Moreover, a high B7 score, defined as high B7-H3 expression and/or high HHLA2 expression, was an independent prognostic predictor for PCa. Of note, a high B7 score was negatively correlated with CD8+ TILs. Importantly, a new immune classification, based on the B7 score and CD8+ TILs, successfully stratified OS and CSS in PCa.Both B7-H3 and HHLA2 have a critical impact on the immunosuppressive microenvironment, and the B7 score could be used as an independent prognostic factor for PCa. The B7 score combined with CD8+ TILs could be used as a new immune classification to stratify the risk of death, especially cancer-related death, for patients with PCa. These findings may provide insights that could improve response to immune-related comprehensive therapy for PCa in the future.CONCLUSIONSBoth B7-H3 and HHLA2 have a critical impact on the immunosuppressive microenvironment, and the B7 score could be used as an independent prognostic factor for PCa. The B7 score combined with CD8+ TILs could be used as a new immune classification to stratify the risk of death, especially cancer-related death, for patients with PCa. These findings may provide insights that could improve response to immune-related comprehensive therapy for PCa in the future. Although immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers, exhibit prominent antitumor effects against numerous malignancies, their benefit for patients with prostate cancer (PCa) has been somewhat marginal. This study aimed to assess the feasibility of B7-H3 or HHLA2 as alternative immunotherapeutic targets in PCa. Immunohistochemistry was performed to evaluate the expression pattern of PD-L1, B7-H3 and HHLA2 and the infiltration of CD8 and Foxp3 lymphocytes in 239 PCa tissues from two independent cohorts. The correlations between B7-H3 and HHLA2 and clinicopathological features, including the presence of CD8 and Foxp3 tumor-infiltrating lymphocytes (TILs), were explored. HHLA2 expression was much higher than PD-L1 expression but lower than B7-H3 expression in PCa tissues. High expression of both B7-H3 and HHLA2 was significantly associated with higher Gleason score and tumor stage, lymph node metastasis and dismal overall survival (OS) and cancer-specific survival (CSS). Moreover, a high B7 score, defined as high B7-H3 expression and/or high HHLA2 expression, was an independent prognostic predictor for PCa. Of note, a high B7 score was negatively correlated with CD8 TILs. Importantly, a new immune classification, based on the B7 score and CD8 TILs, successfully stratified OS and CSS in PCa. Both B7-H3 and HHLA2 have a critical impact on the immunosuppressive microenvironment, and the B7 score could be used as an independent prognostic factor for PCa. The B7 score combined with CD8 TILs could be used as a new immune classification to stratify the risk of death, especially cancer-related death, for patients with PCa. These findings may provide insights that could improve response to immune-related comprehensive therapy for PCa in the future. BackgroundAlthough immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers, exhibit prominent antitumor effects against numerous malignancies, their benefit for patients with prostate cancer (PCa) has been somewhat marginal. This study aimed to assess the feasibility of B7-H3 or HHLA2 as alternative immunotherapeutic targets in PCa.MethodsImmunohistochemistry was performed to evaluate the expression pattern of PD-L1, B7-H3 and HHLA2 and the infiltration of CD8+ and Foxp3+ lymphocytes in 239 PCa tissues from two independent cohorts. The correlations between B7-H3 and HHLA2 and clinicopathological features, including the presence of CD8+ and Foxp3+ tumor-infiltrating lymphocytes (TILs), were explored.ResultsHHLA2 expression was much higher than PD-L1 expression but lower than B7-H3 expression in PCa tissues. High expression of both B7-H3 and HHLA2 was significantly associated with higher Gleason score and tumor stage, lymph node metastasis and dismal overall survival (OS) and cancer-specific survival (CSS). Moreover, a high B7 score, defined as high B7-H3 expression and/or high HHLA2 expression, was an independent prognostic predictor for PCa. Of note, a high B7 score was negatively correlated with CD8+ TILs. Importantly, a new immune classification, based on the B7 score and CD8+ TILs, successfully stratified OS and CSS in PCa.ConclusionsBoth B7-H3 and HHLA2 have a critical impact on the immunosuppressive microenvironment, and the B7 score could be used as an independent prognostic factor for PCa. The B7 score combined with CD8+ TILs could be used as a new immune classification to stratify the risk of death, especially cancer-related death, for patients with PCa. These findings may provide insights that could improve response to immune-related comprehensive therapy for PCa in the future. Background Although immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers, exhibit prominent antitumor effects against numerous malignancies, their benefit for patients with prostate cancer (PCa) has been somewhat marginal. This study aimed to assess the feasibility of B7-H3 or HHLA2 as alternative immunotherapeutic targets in PCa.Methods Immunohistochemistry was performed to evaluate the expression pattern of PD-L1, B7-H3 and HHLA2 and the infiltration of CD8+ and Foxp3+ lymphocytes in 239 PCa tissues from two independent cohorts. The correlations between B7-H3 and HHLA2 and clinicopathological features, including the presence of CD8+ and Foxp3+ tumor-infiltrating lymphocytes (TILs), were explored.Results HHLA2 expression was much higher than PD-L1 expression but lower than B7-H3 expression in PCa tissues. High expression of both B7-H3 and HHLA2 was significantly associated with higher Gleason score and tumor stage, lymph node metastasis and dismal overall survival (OS) and cancer-specific survival (CSS). Moreover, a high B7 score, defined as high B7-H3 expression and/or high HHLA2 expression, was an independent prognostic predictor for PCa. Of note, a high B7 score was negatively correlated with CD8+ TILs. Importantly, a new immune classification, based on the B7 score and CD8+ TILs, successfully stratified OS and CSS in PCa.Conclusions Both B7-H3 and HHLA2 have a critical impact on the immunosuppressive microenvironment, and the B7 score could be used as an independent prognostic factor for PCa. The B7 score combined with CD8+ TILs could be used as a new immune classification to stratify the risk of death, especially cancer-related death, for patients with PCa. These findings may provide insights that could improve response to immune-related comprehensive therapy for PCa in the future. |
| Author | Li, Kaiwen Zhan, Xiangyu Huang, Jian Huang, Hai Zhou, Qianghua Yao, Wei Lai, Yiming Yao, Kai Peng, Shirong Cai, Wenli Wang, Qiong Zang, Xingxing Xu, Kewei |
| AuthorAffiliation | 4 Department of Radiology , Massachusetts General Hospital , Boston , Massachusetts , USA 6 Guangdong Provincial Clinical Research Center for Urological Diseases , Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University , Guangzhou , Guangdong , China 2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University , Guangzhou , Guangdong , China 1 Department of Urology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , Guangdong , China 5 Department of Oncology , Albert Einstein College of Medicine , Bronx , New York , USA 3 Department of urology , Sun Yat-sen University Cancer Center , Guangzhou , Guangdong , China 7 Department of Urology , The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital , Qingyuan , Guangdong , china |
| AuthorAffiliation_xml | – name: 3 Department of urology , Sun Yat-sen University Cancer Center , Guangzhou , Guangdong , China – name: 4 Department of Radiology , Massachusetts General Hospital , Boston , Massachusetts , USA – name: 5 Department of Oncology , Albert Einstein College of Medicine , Bronx , New York , USA – name: 6 Guangdong Provincial Clinical Research Center for Urological Diseases , Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University , Guangzhou , Guangdong , China – name: 2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University , Guangzhou , Guangdong , China – name: 1 Department of Urology , Sun Yat-sen Memorial Hospital, Sun Yat-sen University , Guangzhou , Guangdong , China – name: 7 Department of Urology , The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital , Qingyuan , Guangdong , china |
| Author_xml | – sequence: 1 givenname: Qianghua surname: Zhou fullname: Zhou, Qianghua email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China – sequence: 2 givenname: Kaiwen surname: Li fullname: Li, Kaiwen email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China – sequence: 3 givenname: Yiming surname: Lai fullname: Lai, Yiming email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China – sequence: 4 givenname: Kai surname: Yao fullname: Yao, Kai email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Department of urology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China – sequence: 5 givenname: Qiong surname: Wang fullname: Wang, Qiong email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China – sequence: 6 givenname: Xiangyu surname: Zhan fullname: Zhan, Xiangyu email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China – sequence: 7 givenname: Shirong surname: Peng fullname: Peng, Shirong email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China – sequence: 8 givenname: Wenli surname: Cai fullname: Cai, Wenli email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA – sequence: 9 givenname: Wei surname: Yao fullname: Yao, Wei email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Department of Oncology, Albert Einstein College of Medicine, Bronx, New York, USA – sequence: 10 givenname: Xingxing surname: Zang fullname: Zang, Xingxing email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Department of Oncology, Albert Einstein College of Medicine, Bronx, New York, USA – sequence: 11 givenname: Kewei surname: Xu fullname: Xu, Kewei email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Guangdong Provincial Clinical Research Center for Urological Diseases, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China – sequence: 12 givenname: Jian surname: Huang fullname: Huang, Jian email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Guangdong Provincial Clinical Research Center for Urological Diseases, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China – sequence: 13 givenname: Hai orcidid: 0000-0002-2013-073X surname: Huang fullname: Huang, Hai email: huangh9@mail.sysu.edu.cn, huangj8@mail.sysu.edu.cn, xukewei@mail.sysu.edu.cn organization: Department of Urology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, Guangdong, china |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34417325$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkk1rFjEQgINUbK29e5IFL0JZzffHRailaqXgpZ5DNsnWLLvJa7Ir9N-bfbeVtgc9ZZI88zCZzEtwEFP0ALxG8D1ChH8YwmxbDDFqIcSUsWfgCEOGWkQxP3gQH4KTUgYIIYKESClfgENCKRIEsyPw7ZNoik3ZNya65rqxfhybEPswztnMIcWm7IP-tgnTtERf92ZeSmWaXU7rxjfWROvzK_C8N2PxJ3frMfjx-eL6_Gt79f3L5fnZVdsxzOfW9R0zghHcSU4EF9QLyKWjhjiDemesRZR2lUHMyb6XRlEmrBLCYuKpcuQYXG5el8ygdzlMJt_qZILeH6R8o02egx29Fp2rKmWoMpJagTunqpZ2SFGFIIXV9XFz7ZZu8s76WF87PpI-vonhp75Jv7UkEhGyCt7dCXL6tfgy6ymUtYkm-rQUjRknFGNOVUXfPkGHtORYW1UpRTiVQshKvXlY0d9S7r-sAnwDbG1_yb7XNsz7r6oFhlEjqNfx0Ot46HU89DYeNRE-Sbx3_yPldEvppuH_9B8yrMnK |
| CitedBy_id | crossref_primary_10_1186_s12957_024_03409_2 crossref_primary_10_1007_s00262_024_03791_6 crossref_primary_10_1186_s13046_023_02764_4 crossref_primary_10_3390_ijms25094760 crossref_primary_10_1016_j_ebiom_2022_103987 crossref_primary_10_1038_s41423_023_01019_8 crossref_primary_10_3390_molecules28083356 crossref_primary_10_1186_s13046_024_02962_8 crossref_primary_10_1007_s12672_024_01674_x crossref_primary_10_1016_j_lfs_2023_121659 crossref_primary_10_1016_j_jare_2022_07_013 crossref_primary_10_1016_j_tice_2024_102530 crossref_primary_10_1016_j_canlet_2024_216713 crossref_primary_10_1186_s13045_022_01364_7 crossref_primary_10_3892_ijo_2022_5402 crossref_primary_10_1016_j_intimp_2023_111186 crossref_primary_10_1186_s42269_023_01106_w crossref_primary_10_5534_wjmh_240061 crossref_primary_10_1111_hel_12999 crossref_primary_10_3389_fimmu_2022_984172 crossref_primary_10_1093_jleuko_qiae158 crossref_primary_10_3389_fimmu_2024_1472626 crossref_primary_10_1111_jop_13514 |
| Cites_doi | 10.1038/nrclinonc.2014.72 10.1186/s40425-018-0353-7 10.1158/0008-5472.CAN-07-1068 10.1007/s00262-012-1278-5 10.1016/j.ejca.2020.03.033 10.1158/0008-5472.CAN-15-0255 10.1038/ncomms3043 10.1038/pcan.2015.39 10.1038/sj.bjc.6605375 10.1056/NEJMoa1510665 10.1073/pnas.0405259101 10.1186/1471-2407-9-463 10.1038/s41416-020-0755-4 10.1038/sj.gt.3302070 10.1038/nrurol.2014.243 10.1016/j.semcancer.2017.09.004 10.1158/1078-0432.CCR-08-2262 10.1001/jamaoncol.2018.0013 10.1002/cac2.12001 10.1038/pcan.2016.49 10.1186/s40425-019-0554-8 10.1002/pros.24068 10.1097/SLA.0b013e3181f1939d 10.3322/caac.21551 10.1158/1078-0432.CCR-15-3071 10.1007/s00018-020-03459-1 10.1001/jama.2017.7248 10.1073/pnas.1303524110 10.1158/1078-0432.CCR-14-1495 10.1016/S1470-2045(15)70054-9 10.4049/jimmunol.173.4.2500 10.1158/1078-0432.CCR-12-0715 10.1056/NEJMoa1412082 10.1073/pnas.0802423105 10.1038/85339 10.1016/j.canlet.2015.06.021 10.1073/pnas.0709802104 10.1136/jitc-2019-000157 |
| ContentType | Journal Article |
| Copyright | Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 |
| Copyright_xml | – notice: Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. – notice: 2021 Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2021 |
| DBID | 9YT ACMMV AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1136/jitc-2021-002455 |
| DatabaseName | BMJ Open Access Journals BMJ Journals:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Open Access Full Text |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: ACMMV name: BMJ Journals:Open Access url: https://journals.bmj.com/ sourceTypes: Publisher – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2051-1426 |
| ExternalDocumentID | oai_doaj_org_article_7bd4bb9a49a84c72bd9a154b19491040 PMC8381330 34417325 10_1136_jitc_2021_002455 jitc |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | 4.4 53G 5VS 7X7 88E 8FI 8FJ 9YT ABUWG ACGFS ACMMV ADBBV ADRAZ AFKRA AHBYD AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS ASPBG AVWKF BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU DIK EBS FYUFA GROUPED_DOAJ HMCUK HYE IAO IHR IHW INH INR KQ8 M1P M48 M~E OK1 PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RMJ RPM RSV SOJ UKHRP AAYXX ADUKV AHSBF CITATION EJD H13 ITC PHGZM ROL CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-b526t-dfb5a7532b8637674e7068d4a3da1fdacc144bb5a15d8ff8a9457c977c23e49d3 |
| IEDL.DBID | 9YT |
| ISSN | 2051-1426 |
| IngestDate | Wed Aug 27 01:29:12 EDT 2025 Thu Aug 21 14:14:34 EDT 2025 Tue Aug 05 10:28:19 EDT 2025 Fri Jul 25 21:11:18 EDT 2025 Thu Apr 03 07:06:03 EDT 2025 Tue Jul 01 01:55:53 EDT 2025 Thu Apr 24 22:59:54 EDT 2025 Thu Apr 24 22:50:24 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Keywords | tumor microenvironment tumor biomarkers costimulatory and inhibitory T-cell receptors prostatic neoplasms |
| Language | English |
| License | This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/. Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b526t-dfb5a7532b8637674e7068d4a3da1fdacc144bb5a15d8ff8a9457c977c23e49d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-2013-073X |
| OpenAccessLink | http://dx.doi.org/10.1136/jitc-2021-002455 |
| PMID | 34417325 |
| PQID | 2593648778 |
| PQPubID | 2040222 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_7bd4bb9a49a84c72bd9a154b19491040 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8381330 proquest_miscellaneous_2563422649 proquest_journals_2593648778 pubmed_primary_34417325 crossref_citationtrail_10_1136_jitc_2021_002455 crossref_primary_10_1136_jitc_2021_002455 bmj_primary_10_1136_jitc_2021_002455 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-08-00 |
| PublicationDateYYYYMMDD | 2021-08-01 |
| PublicationDate_xml | – month: 08 year: 2021 text: 2021-08-00 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London – name: BMA House, Tavistock Square, London, WC1H 9JR |
| PublicationSeriesTitle | Original research |
| PublicationTitle | Journal for immunotherapy of cancer |
| PublicationTitleAlternate | J Immunother Cancer |
| PublicationYear | 2021 |
| Publisher | BMJ Publishing Group LTD BMJ Publishing Group |
| Publisher_xml | – name: BMJ Publishing Group LTD – name: BMJ Publishing Group |
| References | Siegel, Miller, Jemal 2019; 69 Hashiguchi, Kobori, Ritprajak 2008; 105 Martin, Nirschl, Nirschl 2015; 18 Suh, Wang, Jheon 2004; 101 Arigami, Narita, Mizuno 2010; 252 Roth, Sheinin, Lohse 2007; 67 Rizvi, Mazières, Planchard 2015; 16 Sun, Vale, Leung 2003; 10 Axelrod, Johnson, Balko 2018; 52 Chavin, Sheinin, Crispen 2009; 15 Benzon, Zhao, Haffner 2017; 20 Prasad, Nguyen, Li 2004; 173 Läubli, Balmelli, Kaufmann 2018; 6 Loo, Alderson, Chen 2012; 18 Zhou, Han, Lu 2020; 40 Zang, Thompson, Al-Ahmadie 2007; 104 Zhao, Chinai, Buhl 2013; 110 Claessens, Helsen, Prekovic 2014; 11 Yim, Koh, Kim 2020; 133 Katzenwadel, Wolf 2015; 367 Jing, Fu, Yi 2019; 7 Janakiram, Chinai, Fineberg 2015; 21 Fuchs, Doi, Jang 2018; 4 Robert, Long, Brady 2015; 372 Cheng, Janakiram, Borczuk 2017; 23 Yamato, Sho, Nomi 2009; 101 Zhou, Li, Chen 2020; 8 Litwin, Tan 2017; 317 Zhu, Yao, Iliopoulou 2013; 4 Yang, Attwood, Bshara 2021; 81 Boor, Sideras, Biermann 2020; 122 Chapoval, Ni, Lau 2001; 2 Wong, Ferraldeschi, Attard 2014; 11 Motzer, Escudier, McDermott 2015; 373 Loos, Hedderich, Ottenhausen 2009; 9 Teng, Ngiow, Ribas 2015; 75 Jafari, Molavi, Kahroba 2020; 77 Sun, Gao, Qiu 2012; 61 Robert (2021102823400544000_9.8.e002455.8) 2015; 372 Zhao (2021102823400544000_9.8.e002455.23) 2013; 110 Roth (2021102823400544000_9.8.e002455.11) 2007; 67 Zhou (2021102823400544000_9.8.e002455.30) 2020; 40 Janakiram (2021102823400544000_9.8.e002455.29) 2015; 21 Zang (2021102823400544000_9.8.e002455.22) 2007; 104 Zhu (2021102823400544000_9.8.e002455.24) 2013; 4 Rizvi (2021102823400544000_9.8.e002455.7) 2015; 16 Arigami (2021102823400544000_9.8.e002455.15) 2010; 252 Chavin (2021102823400544000_9.8.e002455.33) 2009; 15 Martin (2021102823400544000_9.8.e002455.13) 2015; 18 Sun (2021102823400544000_9.8.e002455.14) 2012; 61 Siegel (2021102823400544000_9.8.e002455.1) 2019; 69 Katzenwadel (2021102823400544000_9.8.e002455.3) 2015; 367 Loos (2021102823400544000_9.8.e002455.17) 2009; 9 Cheng (2021102823400544000_9.8.e002455.27) 2017; 23 Jing (2021102823400544000_9.8.e002455.28) 2019; 7 Läubli (2021102823400544000_9.8.e002455.31) 2018; 6 Chapoval (2021102823400544000_9.8.e002455.18) 2001; 2 Jafari (2021102823400544000_9.8.e002455.12) 2020; 77 Suh (2021102823400544000_9.8.e002455.20) 2004; 101 Claessens (2021102823400544000_9.8.e002455.5) 2014; 11 Hashiguchi (2021102823400544000_9.8.e002455.21) 2008; 105 Zhou (2021102823400544000_9.8.e002455.25) 2020; 8 Fuchs (2021102823400544000_9.8.e002455.10) 2018; 4 Yim (2021102823400544000_9.8.e002455.16) 2020; 133 Loo (2021102823400544000_9.8.e002455.37) 2012; 18 Prasad (2021102823400544000_9.8.e002455.19) 2004; 173 Yamato (2021102823400544000_9.8.e002455.36) 2009; 101 Benzon (2021102823400544000_9.8.e002455.34) 2017; 20 Yang (2021102823400544000_9.8.e002455.32) 2021; 81 Litwin (2021102823400544000_9.8.e002455.2) 2017; 317 Teng (2021102823400544000_9.8.e002455.38) 2015; 75 Sun (2021102823400544000_9.8.e002455.35) 2003; 10 Motzer (2021102823400544000_9.8.e002455.6) 2015; 373 Boor (2021102823400544000_9.8.e002455.26) 2020; 122 Wong (2021102823400544000_9.8.e002455.4) 2014; 11 Axelrod (2021102823400544000_9.8.e002455.9) 2018; 52 |
| References_xml | – volume: 11 start-page: 365 year: 2014 article-title: Evolution of androgen receptor targeted therapy for advanced prostate cancer publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2014.72 – volume: 6 year: 2018 article-title: Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0353-7 – volume: 67 start-page: 7893 year: 2007 article-title: B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-1068 – volume: 61 start-page: 2171 year: 2012 article-title: B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-012-1278-5 – volume: 133 start-page: 74 year: 2020 article-title: Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.03.033 – volume: 75 start-page: 2139 year: 2015 article-title: Classifying cancers based on T-cell infiltration and PD-L1 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-0255 – volume: 4 year: 2013 article-title: B7-H5 costimulates human T cells via CD28H publication-title: Nat Commun doi: 10.1038/ncomms3043 – volume: 18 start-page: 325 year: 2015 article-title: Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2015.39 – volume: 101 start-page: 1709 year: 2009 article-title: Clinical importance of B7-H3 expression in human pancreatic cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605375 – volume: 373 start-page: 1803 year: 2015 article-title: Nivolumab versus everolimus in advanced renal-cell carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1510665 – volume: 101 start-page: 12969 year: 2004 article-title: The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0405259101 – volume: 9 year: 2009 article-title: Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer publication-title: BMC Cancer doi: 10.1186/1471-2407-9-463 – volume: 122 start-page: 1211 year: 2020 article-title: HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis publication-title: Br J Cancer doi: 10.1038/s41416-020-0755-4 – volume: 10 start-page: 1728 year: 2003 article-title: Mouse B7-H3 induces antitumor immunity publication-title: Gene Ther doi: 10.1038/sj.gt.3302070 – volume: 11 start-page: 712 year: 2014 article-title: Emerging mechanisms of enzalutamide resistance in prostate cancer publication-title: Nat Rev Urol doi: 10.1038/nrurol.2014.243 – volume: 52 start-page: 207 year: 2018 article-title: Emerging biomarkers for cancer immunotherapy in melanoma publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2017.09.004 – volume: 15 start-page: 2174 year: 2009 article-title: Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-2262 – volume: 4 year: 2018 article-title: Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.0013 – volume: 40 start-page: 3 year: 2020 article-title: Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients publication-title: Cancer Commun doi: 10.1002/cac2.12001 – volume: 20 start-page: 28 year: 2017 article-title: Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2016.49 – volume: 7 start-page: 77 year: 2019 article-title: HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1 publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0554-8 – volume: 81 start-page: 20 year: 2021 article-title: High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy publication-title: Prostate doi: 10.1002/pros.24068 – volume: 252 start-page: 1044 year: 2010 article-title: B7-H3 ligand expression by primary breast cancer and associated with regional nodal metastasis publication-title: Ann Surg doi: 10.1097/SLA.0b013e3181f1939d – volume: 69 start-page: 7 year: 2019 article-title: Cancer statistics, 2019 publication-title: CA A Cancer J Clin doi: 10.3322/caac.21551 – volume: 23 start-page: 825 year: 2017 article-title: HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-3071 – volume: 77 start-page: 3693 year: 2020 article-title: Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer publication-title: Cell Mol Life Sci doi: 10.1007/s00018-020-03459-1 – volume: 317 start-page: 2532 year: 2017 article-title: The diagnosis and treatment of prostate cancer: a review publication-title: JAMA doi: 10.1001/jama.2017.7248 – volume: 110 start-page: 9879 year: 2013 article-title: HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1303524110 – volume: 21 start-page: 2359 year: 2015 article-title: Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1495 – volume: 16 start-page: 257 year: 2015 article-title: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70054-9 – volume: 173 start-page: 2500 year: 2004 article-title: Murine B7-H3 is a negative regulator of T cells publication-title: J Immunol doi: 10.4049/jimmunol.173.4.2500 – volume: 18 start-page: 3834 year: 2012 article-title: Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-0715 – volume: 372 start-page: 320 year: 2015 article-title: Nivolumab in previously untreated melanoma without BRAF mutation publication-title: N Engl J Med doi: 10.1056/NEJMoa1412082 – volume: 105 start-page: 10495 year: 2008 article-title: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0802423105 – volume: 2 start-page: 269 year: 2001 article-title: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production publication-title: Nat Immunol doi: 10.1038/85339 – volume: 367 start-page: 12 year: 2015 article-title: Androgen deprivation of prostate cancer: leading to a therapeutic dead end publication-title: Cancer Lett doi: 10.1016/j.canlet.2015.06.021 – volume: 104 start-page: 19458 year: 2007 article-title: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0709802104 – volume: 8 year: 2020 article-title: HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma publication-title: J Immunother Cancer doi: 10.1136/jitc-2019-000157 – volume: 372 start-page: 320 year: 2015 ident: 2021102823400544000_9.8.e002455.8 article-title: Nivolumab in previously untreated melanoma without BRAF mutation publication-title: N Engl J Med doi: 10.1056/NEJMoa1412082 – volume: 110 start-page: 9879 year: 2013 ident: 2021102823400544000_9.8.e002455.23 article-title: HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1303524110 – volume: 23 start-page: 825 year: 2017 ident: 2021102823400544000_9.8.e002455.27 article-title: HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-15-3071 – volume: 7 start-page: 77 year: 2019 ident: 2021102823400544000_9.8.e002455.28 article-title: HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1 publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0554-8 – volume: 61 start-page: 2171 year: 2012 ident: 2021102823400544000_9.8.e002455.14 article-title: B7-H3 is expressed in human hepatocellular carcinoma and is associated with tumor aggressiveness and postoperative recurrence publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-012-1278-5 – volume: 11 start-page: 712 year: 2014 ident: 2021102823400544000_9.8.e002455.5 article-title: Emerging mechanisms of enzalutamide resistance in prostate cancer publication-title: Nat Rev Urol doi: 10.1038/nrurol.2014.243 – volume: 133 start-page: 74 year: 2020 ident: 2021102823400544000_9.8.e002455.16 article-title: Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer publication-title: Eur J Cancer doi: 10.1016/j.ejca.2020.03.033 – volume: 104 start-page: 19458 year: 2007 ident: 2021102823400544000_9.8.e002455.22 article-title: B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0709802104 – volume: 101 start-page: 1709 year: 2009 ident: 2021102823400544000_9.8.e002455.36 article-title: Clinical importance of B7-H3 expression in human pancreatic cancer publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605375 – volume: 367 start-page: 12 year: 2015 ident: 2021102823400544000_9.8.e002455.3 article-title: Androgen deprivation of prostate cancer: leading to a therapeutic dead end publication-title: Cancer Lett doi: 10.1016/j.canlet.2015.06.021 – volume: 101 start-page: 12969 year: 2004 ident: 2021102823400544000_9.8.e002455.20 article-title: The immune regulatory protein B7-H3 promotes osteoblast differentiation and bone mineralization publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0405259101 – volume: 105 start-page: 10495 year: 2008 ident: 2021102823400544000_9.8.e002455.21 article-title: Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0802423105 – volume: 21 start-page: 2359 year: 2015 ident: 2021102823400544000_9.8.e002455.29 article-title: Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-1495 – volume: 77 start-page: 3693 year: 2020 ident: 2021102823400544000_9.8.e002455.12 article-title: Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer publication-title: Cell Mol Life Sci doi: 10.1007/s00018-020-03459-1 – volume: 4 year: 2018 ident: 2021102823400544000_9.8.e002455.10 article-title: Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2018.0013 – volume: 11 start-page: 365 year: 2014 ident: 2021102823400544000_9.8.e002455.4 article-title: Evolution of androgen receptor targeted therapy for advanced prostate cancer publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2014.72 – volume: 6 year: 2018 ident: 2021102823400544000_9.8.e002455.31 article-title: Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0353-7 – volume: 9 year: 2009 ident: 2021102823400544000_9.8.e002455.17 article-title: Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer publication-title: BMC Cancer doi: 10.1186/1471-2407-9-463 – volume: 317 start-page: 2532 year: 2017 ident: 2021102823400544000_9.8.e002455.2 article-title: The diagnosis and treatment of prostate cancer: a review publication-title: JAMA doi: 10.1001/jama.2017.7248 – volume: 18 start-page: 3834 year: 2012 ident: 2021102823400544000_9.8.e002455.37 article-title: Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-12-0715 – volume: 81 start-page: 20 year: 2021 ident: 2021102823400544000_9.8.e002455.32 article-title: High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy publication-title: Prostate doi: 10.1002/pros.24068 – volume: 18 start-page: 325 year: 2015 ident: 2021102823400544000_9.8.e002455.13 article-title: Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2015.39 – volume: 122 start-page: 1211 year: 2020 ident: 2021102823400544000_9.8.e002455.26 article-title: HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis publication-title: Br J Cancer doi: 10.1038/s41416-020-0755-4 – volume: 52 start-page: 207 year: 2018 ident: 2021102823400544000_9.8.e002455.9 article-title: Emerging biomarkers for cancer immunotherapy in melanoma publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2017.09.004 – volume: 40 start-page: 3 year: 2020 ident: 2021102823400544000_9.8.e002455.30 article-title: Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients publication-title: Cancer Commun doi: 10.1002/cac2.12001 – volume: 20 start-page: 28 year: 2017 ident: 2021102823400544000_9.8.e002455.34 article-title: Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis publication-title: Prostate Cancer Prostatic Dis doi: 10.1038/pcan.2016.49 – volume: 252 start-page: 1044 year: 2010 ident: 2021102823400544000_9.8.e002455.15 article-title: B7-H3 ligand expression by primary breast cancer and associated with regional nodal metastasis publication-title: Ann Surg doi: 10.1097/SLA.0b013e3181f1939d – volume: 15 start-page: 2174 year: 2009 ident: 2021102823400544000_9.8.e002455.33 article-title: Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-2262 – volume: 4 year: 2013 ident: 2021102823400544000_9.8.e002455.24 article-title: B7-H5 costimulates human T cells via CD28H publication-title: Nat Commun doi: 10.1038/ncomms3043 – volume: 8 year: 2020 ident: 2021102823400544000_9.8.e002455.25 article-title: HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma publication-title: J Immunother Cancer doi: 10.1136/jitc-2019-000157 – volume: 2 start-page: 269 year: 2001 ident: 2021102823400544000_9.8.e002455.18 article-title: B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production publication-title: Nat Immunol doi: 10.1038/85339 – volume: 373 start-page: 1803 year: 2015 ident: 2021102823400544000_9.8.e002455.6 article-title: Nivolumab versus everolimus in advanced renal-cell carcinoma publication-title: N Engl J Med doi: 10.1056/NEJMoa1510665 – volume: 16 start-page: 257 year: 2015 ident: 2021102823400544000_9.8.e002455.7 article-title: Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70054-9 – volume: 173 start-page: 2500 year: 2004 ident: 2021102823400544000_9.8.e002455.19 article-title: Murine B7-H3 is a negative regulator of T cells publication-title: J Immunol doi: 10.4049/jimmunol.173.4.2500 – volume: 75 start-page: 2139 year: 2015 ident: 2021102823400544000_9.8.e002455.38 article-title: Classifying cancers based on T-cell infiltration and PD-L1 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-0255 – volume: 67 start-page: 7893 year: 2007 ident: 2021102823400544000_9.8.e002455.11 article-title: B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-07-1068 – volume: 69 start-page: 7 year: 2019 ident: 2021102823400544000_9.8.e002455.1 article-title: Cancer statistics, 2019 publication-title: CA A Cancer J Clin doi: 10.3322/caac.21551 – volume: 10 start-page: 1728 year: 2003 ident: 2021102823400544000_9.8.e002455.35 article-title: Mouse B7-H3 induces antitumor immunity publication-title: Gene Ther doi: 10.1038/sj.gt.3302070 |
| SSID | ssj0001033888 |
| Score | 2.3321247 |
| Snippet | BackgroundAlthough immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers,... Although immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers, exhibit... Background Although immune checkpoint inhibitors (ICIs), especially programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) axis blockers,... |
| SourceID | doaj pubmedcentral proquest pubmed crossref bmj |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | e002455 |
| SubjectTerms | Adult Aged Aged, 80 and over Biomarkers, Tumor - metabolism Cancer Cancer therapies Humans Immune checkpoint inhibitors Immunotherapy Immunotherapy Biomarkers Kidney cancer Ligands Lung cancer Lymphocytes, Tumor-Infiltrating - immunology Male Medical prognosis Middle Aged Prostate cancer Prostatic Neoplasms - immunology Retrospective Studies Tumor Microenvironment Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Open Access Full Text dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7iQbyIb-uLCF48lE2bNEmPKsqyoCcFbyGv4opW2cfBf-9M2112RfTitUlKOvnCzNdkviHkHGIArbSrUhYLmQrJYmoLVN1nsgw6V8wLzB2-u5f9RzF4Kp4WSn3hnbBWHrg1XE-5IJwrrSitFl7lLpQW3L4D8g2eTjRsHXzeAplq_q4woF5az84luey9DCceIJEDecbTRvQl7u1lyRs1ov0_RZrfL0wueKDbTbLRhY70sp3yFlmJ9TZZu-sOx3fI4ErRMapSUlsH-kDxnzwFAA1fO2lc2mrkVp90iFkhkWI20XQMfegHJn9A2Ek9omC0Sx5vbx6u-2lXKiF1RS4naahcYYF55E5L1GcRUTGpg7A82KwK1nsgTg76ZEXQVaVtKQrlIfbzOY-iDHyPrNbvdTwg1HHBhQxZldlMZJ5pPPFVMrDgy0zELCHnYDjz0YphmIZEcGnQvgbta1r7JqQ3s6zxndw4Vr14_WXExXzE32-_wsWa90OR7OYBQMd00DF_QSchx7OlNt3OHZscSxwCi1M6IWfzZthzuGi2ju9T7CN5k4FcJmS_RcZ8JhxruvEcZqiWMLM01eWWevjc6HpriJ44Z4f_8W1HZL0FO15VPCark9E0nkD4NHGnzU75AqDRFAc priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELagSIgL4k2gICP1wiFaO3b8OCGKqKpK5dRKe7P8CmzVZpd9HPj3zCTeLYtQucZ2ZI_H9jcezzeEHAEGMNqErma5VbVULNe-RdZ9pmwyjWZRYuzw-Td1einPpu20XLityrPK7Z44bNRpHvGOfNJg6jlA19p8WvysMWsUeldLCo375AFSl-GTLj3Vt3csDAwwY7beSaEmV7N1BMVowIRGnyOeKOHmau9MGqj7_4U3_342-cc5dPKEPC4Akn4eZ_wpuZf7Z-TheXGRPydnx5qukJuS-j7RC4o38xTUaHZdCHLpyJTb_aIzjA3JFGOKNiuoQxcYAgLgk0bUheULcnny9eLLaV0SJtShbdS6Tl1oPdgfTTAKWVpk1kyZJL1InnfJxwjmU4A6vE2m64y3stUREGBsRJY2iZfkoJ_3-TWhQUghVeId91zyyAz6fbVKLEXLZeYVOQLBucVIieEGU0Ioh_J1KF83yrcik61kXSyk45j74vqOFh93Lf7_92OcrF09pMoePsyX311ZeU6HBGO2XlpvZNRNSBbGLwO3EqCSZBU53E61K-t35W61rSIfdsWw8nDSfJ_nG6yjxBCHbCvyatSMXU8EZnYTDfRQ7-nMXlf3S_rZj4Hd2wCGEoK9ubtbb8mjUY3xKeIhOVgvN_kdwKN1eD-sgd9Psgv- priority: 102 providerName: ProQuest – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagSIgL4k1KQUbqhUOoEzt-HBCiiKqqtJy6Um-WX4GtttmyD4n--84k3oVFK7hwje3Inof8je35hpBDwABaad-WLDWyFJKl0jXIus-kibpWLAjMHR59ladjcXbRXPxKj84CXOwM7bCe1Hg-ff_zx81HcPgPuSLJ0eVkGUDbNcTFeJHY3CX3YF9S6KajDPb7ExcG4ZjW67vKHQNhf_FXl1s7VE_kvwt9_vmI8rdd6eQReZjhJP006P8xuZO6J-T-KF-YPyVnx4oukKmSui7Sc4rn9BSWOZlmulw68Oa2N3SCmSKJYobRagF96DUmhAAUpQEtY_6MjE--nH8-LXP5hNI3tVyWsfWNg2ik9loiZ4tIikkdhePRVW10IUAw5aFP1UTdttoZ0agAeDDUPAkT-XOy18269JJQzwUXMlZt5SpRBabxFljJyGIwlUhVQQ5BcPZ6IMiwfWDBpUX5WpSvHeRbkKO1ZG3IFORYCWP6lxHvNiP-_fdjVNamHxJn9x9m8282-6FVPsKajRPGaRFU7aOB9QtfGQHASbCCHKxVbdfGaGssewiRndIFebtpBj9EpbkuzVbYR_I-K9kU5MVgGZuZcKzzxmuYodqyma2pbrd0k-8917cGRMU52_8fa3tFHgzGjs8XD8jecr5KrwFSLf2b3lNuAcwEHAc priority: 102 providerName: Scholars Portal |
| Title | B7 score and T cell infiltration stratify immune status in prostate cancer |
| URI | https://jitc.bmj.com/content/9/8/e002455.full https://www.ncbi.nlm.nih.gov/pubmed/34417325 https://www.proquest.com/docview/2593648778 https://www.proquest.com/docview/2563422649 https://pubmed.ncbi.nlm.nih.gov/PMC8381330 https://doaj.org/article/7bd4bb9a49a84c72bd9a154b19491040 |
| Volume | 9 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3da9swED-WFkpfxr7ntgsa9GUPprIlS_JjU1pKIWWMdGRPQh82S2nd0iQP--93ZzvpUsq2Fxusk5HuTuhOp_sdwCHaAEYbX6e8KlQqFa9SVxDqPldlNLnmQVLu8PhSnV_Ji2kxfYTJeRLBz4Q6up4tAsoyR6-XwoTFALZbSBbS5h-Tx_MUjs6WMatI5DMdd2FHUMEtQWWxB_72emMrahH7nzMzn96W_GP7OXsFL3u7kR13gn4NL6rmDeyM-8j4W7gYaTYnSErmmsgmjA7kGWrP7KbHxWUdQG79i80oJaRilEq0nCMNu6fMD7Q5WSAVeHgHV2enk5PztK-TkPoiV4s01r5w6Hbk3igCZ5GV5spE6UR0WR1dCOg1eaTJimjq2rhSFjqg4RdyUckyivew1dw11UdgXkghVczqzGUyC9xQuFeryGMoM1llCRwi4-x9h4RhWw9CKEustsRq27E6gaMVZ23oscap5MXNX3p8Wff4999HJKw1HSFktx9QbWy_4Kz2EedcOlk6I4POfSxx_tJnpUQLSfIEDlaitv2ynduc6huiC6dNAp_XzbjgSGiuqe6WRKNEm35cJvCh04z1SFb6lYDe0JmNoW62NLOfLai3QdNJCL73fwzeh91Os-km4gFsLR6W1Se0jhZ-CAM91cN2cQxh-_hkPP6O79Hp5ddvw_bEAZ9jaX4D_K0Kvg |
| linkProvider | BMJ Publishing Group Ltd |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKVgIuiDcLBYxUDhyidWLHcQ4IsdBq-9gVQlupN-NXYKuSXfYh1D_Fb2Qmjy2LUDn1mjiRM_5sf5PxfEPILnAAlSlbRCykMhKShcikqLrPZO5VkjEnMHd4OJKDE3F4mp5ukV9tLgweq2zXxGqh9lOH_8h7CZaeA3adqXezHxFWjcLoaltCo4bFUbj4CS7b4u3BRxjf10myvzf-MIiaqgKRTRO5jHxhUwMkPbFKopSJCBmTygvDvYkLb5wDH8NCmzj1qiiUyUWaOaBJLuFB5J7De2-QbcHBlemQ7f7e6NPny786DFw-pdp4KJe9s8nSARQTcNoxyol7mP1-trELVsUC_sVw_z6o-cfOt3-X3GkoK31fY-we2QrlfXJz2ATlH5DDfkYXqIZJTenpmGIsgAJwJ-eNJC-ttXmLCzrBbJRAMYtptYA2dIZJJ0B3qUP0zR-Sk2sx5iPSKadleEKo5YIL6eMiNrGIHVMYac6kZ97lsQhxl-yC4fSsFuHQlfPCpUb7arSvru3bJb3Wsto1MudYbeP8iiferJ_4_9v7OFjrdijOXV2Yzr_qZq7rzHr45tyI3CjhssT6HL5f2DgXQM4E65Kddqh1s2Is9CW-u-TV-jbMdRw0U4bpCttIXmU-513yuEbGuicca8nxBHqYbWBmo6ubd8rJt0pPXAFr45w9vbpbL8mtwXh4rI8PRkfPyO0a0ngQcod0lvNVeA7kbGlfNDOCki_XPQl_A12gSuU |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkSouiHe3FDBSOXCINo4d2zkgRCmrPmjFoZX2ZvwKbFWy230I9a_x65jJY8siVE69JnbkjL-xv_F4ZgjZAQ6glXZlksZcJkKmMbE5Zt1PZRF0plIvMHb4-ETun4nDYT5cI7-6WBi8VtmtifVCHcYez8j7GZaeA3atdL9sr0V82Ru8n1wmWEEKPa1dOY0GIkfx6ieYb7N3B3sw12-ybPDp9ON-0lYYSFyeyXkSSpdbIOyZ0xLTmoioUqmDsDxYVgbrPdgbDtqwPOiy1LYQufJAmXzGoygCh-_eIXcVzxnqmBqq6_OdFIw_rTvPKJf989HcAygzMN_R34m7mftxvrIf1mUD_sV1_76y-cceOHhA7rfklX5o0PaQrMXqEdk4bt3zj8nhrqIzzItJbRXoKUWvAAUIjy7a5Ly0ydJbXtERxqVEivFMixm0oRMMPwHiSz3icPqEnN2KKJ-S9WpcxU1CHRdcyMBKZplgPtXoc1YypMEXTETWIzsgODNp0nGY2ozh0qB8DcrXNPLtkX4nWePbhOdYd-Pihh5vlz3-__VdnKxlO0zTXT8YT7-ZVuuNcgH-ubCisFp4lblQwP8LxwoBNE2kPbLdTbVp146ZuUZ6j7xevgatx0mzVRwvsI3kdQx00SPPGmQsR8KxqhzPYIRqBTMrQ119U42-15nFNfA3ztOtm4f1imyA6pnPBydHz8m9BtF4I3KbrM-ni_gCWNrcvazVgZKvt61_vwElVU21 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=B7+score+and+T+cell+infiltration+stratify+immune+status+in+prostate+cancer&rft.jtitle=Journal+for+immunotherapy+of+cancer&rft.au=Hai+Huang&rft.au=Xingxing+Zang&rft.au=Qiong+Wang&rft.au=Wei+Yao&rft.date=2021-08-01&rft.pub=BMJ+Publishing+Group&rft.eissn=2051-1426&rft.volume=9&rft.issue=8&rft_id=info:doi/10.1136%2Fjitc-2021-002455&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_7bd4bb9a49a84c72bd9a154b19491040 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2051-1426&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2051-1426&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2051-1426&client=summon |